The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma
The role of ipratropium bromide as adjunct therapy to β-agonists in acute asthma is uncertain. We therefore decided to compare the use of 3 mg of salbutamol sulfate alone vs 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide in patients with acute asthma. Patients presenting with acute asthma a...
Gespeichert in:
Veröffentlicht in: | Chest 1997-02, Vol.111 (2), p.311-315 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 315 |
---|---|
container_issue | 2 |
container_start_page | 311 |
container_title | Chest |
container_volume | 111 |
creator | FitzGerald, J. Mark Grunfeld, Anton Pare, Peter D. Levy, Robert D. Newhouse, Michael T. Hodder, Richard Chapman, Kenneth R. |
description | The role of ipratropium bromide as adjunct therapy to β-agonists in acute asthma is uncertain. We therefore decided to compare the use of 3 mg of salbutamol sulfate alone vs 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide in patients with acute asthma. Patients presenting with acute asthma and an FEV1 less than 70% predicted were randomized to a single combination treatment vs salbutamol alone. All patients received supplemental oxygen and methylprednisolone, 125 mg, IV. Baseline measurements were repeated at 45 and 90 min and these included spirometry, oximetry, and vital signs. A total of 952 patients were screened of whom 342 patients were deemed eligible and were randomized in two groups of 171 patients. The mean (SE) age was 30 years (0.9) vs 29 years (0.7), women, 103 (60.2%) vs 110 (64%), 81 (47.4%) never-smoked vs 83 (48.5%), and duration of asthma in years 16.0 (0.8) vs 16.6 (0.8) were no different in the combination vs salbutamol alone group, respectively. Likewise, there was no significant difference in asthma therapy received in the 24 h prior to presentation; most notably, 151 (88.3%) vs 153 (89.5%) received inhaled β-agonists in that period. Baseline FEV1 was 1.62 L (0.05 L) vs 1.53 L (0.03 L), and median time to treatment being received was no different between both groups. Both treatment arms improved significantly. The increase in FEV1 in the combination group was 0.61 L (0.04 L) and in the salbutamol alone group was 0.52 L (0.04 L) at 90 min. There was a trend toward greater bronchodilatation in the combination group, but this did not reach statistical significance. Fewer hospitalizations, 5.9% vs 11.2%, occurred in the combination group, but this did not reach statistical significance. In conclusion, this large multicenter study failed to show a significantly better response to a combination of salbutamol and ipratropium bromide vs salbutamol alone. |
doi_str_mv | 10.1378/chest.111.2.311 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_200457014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0012369215525269</els_id><sourcerecordid>13306884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-2317c7bbc14ae170bb0daeab828da8a14b831ad3b478f9255d9538b2d2352ad63</originalsourceid><addsrcrecordid>eNp1kU9P3DAQxa0KRLfAuVcLcc3isZONfQwr2iKh9gJny_9CjLL21k5A9KP009Z0V8CF02js93szmofQVyBLYC2_MIPL0xIAlnTJAD6hBQgGFWtqdoAWhACt2ErQz-hLzg-k9CBWR-hIkBpEWy_Q39vB4fXogzdqxFd9X6p5xrHH67jRPqjJx4B_Oj2P_o-zuAuTN0MsgEv33mAVyptNbt9ephjKt_WjmmLK-DG_Zz_S4W6MwWEfcGfmyeEuT8NGnaDDXo3Zne7rMbr7dnW7_lHd_Pp-ve5uKsN4M1WUQWtarQ3UykFLtCZWOaU55VZxBbXmDJRlum55L2jTWNEwrqmlrKHKrtgxOtv5blP8PZdzyoc4p1BGSkpI3bQE6iK62IlMijkn18tt8huVniUQ-ZKE_J-ELElIKksShTjf26pcbtsnFYzPrxhtuCAc3owHfz88-eRk3qhx3M6a7Sz3y7w3FjvClaM8epdkNt4F42yhzSRt9B8u9Q_Yz69T</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>200457014</pqid></control><display><type>article</type><title>The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma</title><source>Alma/SFX Local Collection</source><creator>FitzGerald, J. Mark ; Grunfeld, Anton ; Pare, Peter D. ; Levy, Robert D. ; Newhouse, Michael T. ; Hodder, Richard ; Chapman, Kenneth R.</creator><creatorcontrib>FitzGerald, J. Mark ; Grunfeld, Anton ; Pare, Peter D. ; Levy, Robert D. ; Newhouse, Michael T. ; Hodder, Richard ; Chapman, Kenneth R. ; the Canadian Combivent Study Group</creatorcontrib><description>The role of ipratropium bromide as adjunct therapy to β-agonists in acute asthma is uncertain. We therefore decided to compare the use of 3 mg of salbutamol sulfate alone vs 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide in patients with acute asthma. Patients presenting with acute asthma and an FEV1 less than 70% predicted were randomized to a single combination treatment vs salbutamol alone. All patients received supplemental oxygen and methylprednisolone, 125 mg, IV. Baseline measurements were repeated at 45 and 90 min and these included spirometry, oximetry, and vital signs. A total of 952 patients were screened of whom 342 patients were deemed eligible and were randomized in two groups of 171 patients. The mean (SE) age was 30 years (0.9) vs 29 years (0.7), women, 103 (60.2%) vs 110 (64%), 81 (47.4%) never-smoked vs 83 (48.5%), and duration of asthma in years 16.0 (0.8) vs 16.6 (0.8) were no different in the combination vs salbutamol alone group, respectively. Likewise, there was no significant difference in asthma therapy received in the 24 h prior to presentation; most notably, 151 (88.3%) vs 153 (89.5%) received inhaled β-agonists in that period. Baseline FEV1 was 1.62 L (0.05 L) vs 1.53 L (0.03 L), and median time to treatment being received was no different between both groups. Both treatment arms improved significantly. The increase in FEV1 in the combination group was 0.61 L (0.04 L) and in the salbutamol alone group was 0.52 L (0.04 L) at 90 min. There was a trend toward greater bronchodilatation in the combination group, but this did not reach statistical significance. Fewer hospitalizations, 5.9% vs 11.2%, occurred in the combination group, but this did not reach statistical significance. In conclusion, this large multicenter study failed to show a significantly better response to a combination of salbutamol and ipratropium bromide vs salbutamol alone.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.111.2.311</identifier><identifier>PMID: 9041974</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: Elsevier Inc</publisher><subject>acute asthma ; Biological and medical sciences ; bronchodilator therapy ; ipratropium bromide ; Medical sciences ; Pharmacology. Drug treatments ; Respiratory system ; salbutamol</subject><ispartof>Chest, 1997-02, Vol.111 (2), p.311-315</ispartof><rights>1997 The American College of Chest Physicians</rights><rights>1997 INIST-CNRS</rights><rights>Copyright American College of Chest Physicians Feb 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-2317c7bbc14ae170bb0daeab828da8a14b831ad3b478f9255d9538b2d2352ad63</citedby><cites>FETCH-LOGICAL-c385t-2317c7bbc14ae170bb0daeab828da8a14b831ad3b478f9255d9538b2d2352ad63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2589081$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>FitzGerald, J. Mark</creatorcontrib><creatorcontrib>Grunfeld, Anton</creatorcontrib><creatorcontrib>Pare, Peter D.</creatorcontrib><creatorcontrib>Levy, Robert D.</creatorcontrib><creatorcontrib>Newhouse, Michael T.</creatorcontrib><creatorcontrib>Hodder, Richard</creatorcontrib><creatorcontrib>Chapman, Kenneth R.</creatorcontrib><creatorcontrib>the Canadian Combivent Study Group</creatorcontrib><title>The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma</title><title>Chest</title><description>The role of ipratropium bromide as adjunct therapy to β-agonists in acute asthma is uncertain. We therefore decided to compare the use of 3 mg of salbutamol sulfate alone vs 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide in patients with acute asthma. Patients presenting with acute asthma and an FEV1 less than 70% predicted were randomized to a single combination treatment vs salbutamol alone. All patients received supplemental oxygen and methylprednisolone, 125 mg, IV. Baseline measurements were repeated at 45 and 90 min and these included spirometry, oximetry, and vital signs. A total of 952 patients were screened of whom 342 patients were deemed eligible and were randomized in two groups of 171 patients. The mean (SE) age was 30 years (0.9) vs 29 years (0.7), women, 103 (60.2%) vs 110 (64%), 81 (47.4%) never-smoked vs 83 (48.5%), and duration of asthma in years 16.0 (0.8) vs 16.6 (0.8) were no different in the combination vs salbutamol alone group, respectively. Likewise, there was no significant difference in asthma therapy received in the 24 h prior to presentation; most notably, 151 (88.3%) vs 153 (89.5%) received inhaled β-agonists in that period. Baseline FEV1 was 1.62 L (0.05 L) vs 1.53 L (0.03 L), and median time to treatment being received was no different between both groups. Both treatment arms improved significantly. The increase in FEV1 in the combination group was 0.61 L (0.04 L) and in the salbutamol alone group was 0.52 L (0.04 L) at 90 min. There was a trend toward greater bronchodilatation in the combination group, but this did not reach statistical significance. Fewer hospitalizations, 5.9% vs 11.2%, occurred in the combination group, but this did not reach statistical significance. In conclusion, this large multicenter study failed to show a significantly better response to a combination of salbutamol and ipratropium bromide vs salbutamol alone.</description><subject>acute asthma</subject><subject>Biological and medical sciences</subject><subject>bronchodilator therapy</subject><subject>ipratropium bromide</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><subject>salbutamol</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU9P3DAQxa0KRLfAuVcLcc3isZONfQwr2iKh9gJny_9CjLL21k5A9KP009Z0V8CF02js93szmofQVyBLYC2_MIPL0xIAlnTJAD6hBQgGFWtqdoAWhACt2ErQz-hLzg-k9CBWR-hIkBpEWy_Q39vB4fXogzdqxFd9X6p5xrHH67jRPqjJx4B_Oj2P_o-zuAuTN0MsgEv33mAVyptNbt9ephjKt_WjmmLK-DG_Zz_S4W6MwWEfcGfmyeEuT8NGnaDDXo3Zne7rMbr7dnW7_lHd_Pp-ve5uKsN4M1WUQWtarQ3UykFLtCZWOaU55VZxBbXmDJRlum55L2jTWNEwrqmlrKHKrtgxOtv5blP8PZdzyoc4p1BGSkpI3bQE6iK62IlMijkn18tt8huVniUQ-ZKE_J-ELElIKksShTjf26pcbtsnFYzPrxhtuCAc3owHfz88-eRk3qhx3M6a7Sz3y7w3FjvClaM8epdkNt4F42yhzSRt9B8u9Q_Yz69T</recordid><startdate>19970201</startdate><enddate>19970201</enddate><creator>FitzGerald, J. Mark</creator><creator>Grunfeld, Anton</creator><creator>Pare, Peter D.</creator><creator>Levy, Robert D.</creator><creator>Newhouse, Michael T.</creator><creator>Hodder, Richard</creator><creator>Chapman, Kenneth R.</creator><general>Elsevier Inc</general><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>19970201</creationdate><title>The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma</title><author>FitzGerald, J. Mark ; Grunfeld, Anton ; Pare, Peter D. ; Levy, Robert D. ; Newhouse, Michael T. ; Hodder, Richard ; Chapman, Kenneth R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-2317c7bbc14ae170bb0daeab828da8a14b831ad3b478f9255d9538b2d2352ad63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>acute asthma</topic><topic>Biological and medical sciences</topic><topic>bronchodilator therapy</topic><topic>ipratropium bromide</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><topic>salbutamol</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FitzGerald, J. Mark</creatorcontrib><creatorcontrib>Grunfeld, Anton</creatorcontrib><creatorcontrib>Pare, Peter D.</creatorcontrib><creatorcontrib>Levy, Robert D.</creatorcontrib><creatorcontrib>Newhouse, Michael T.</creatorcontrib><creatorcontrib>Hodder, Richard</creatorcontrib><creatorcontrib>Chapman, Kenneth R.</creatorcontrib><creatorcontrib>the Canadian Combivent Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FitzGerald, J. Mark</au><au>Grunfeld, Anton</au><au>Pare, Peter D.</au><au>Levy, Robert D.</au><au>Newhouse, Michael T.</au><au>Hodder, Richard</au><au>Chapman, Kenneth R.</au><aucorp>the Canadian Combivent Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma</atitle><jtitle>Chest</jtitle><date>1997-02-01</date><risdate>1997</risdate><volume>111</volume><issue>2</issue><spage>311</spage><epage>315</epage><pages>311-315</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>The role of ipratropium bromide as adjunct therapy to β-agonists in acute asthma is uncertain. We therefore decided to compare the use of 3 mg of salbutamol sulfate alone vs 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide in patients with acute asthma. Patients presenting with acute asthma and an FEV1 less than 70% predicted were randomized to a single combination treatment vs salbutamol alone. All patients received supplemental oxygen and methylprednisolone, 125 mg, IV. Baseline measurements were repeated at 45 and 90 min and these included spirometry, oximetry, and vital signs. A total of 952 patients were screened of whom 342 patients were deemed eligible and were randomized in two groups of 171 patients. The mean (SE) age was 30 years (0.9) vs 29 years (0.7), women, 103 (60.2%) vs 110 (64%), 81 (47.4%) never-smoked vs 83 (48.5%), and duration of asthma in years 16.0 (0.8) vs 16.6 (0.8) were no different in the combination vs salbutamol alone group, respectively. Likewise, there was no significant difference in asthma therapy received in the 24 h prior to presentation; most notably, 151 (88.3%) vs 153 (89.5%) received inhaled β-agonists in that period. Baseline FEV1 was 1.62 L (0.05 L) vs 1.53 L (0.03 L), and median time to treatment being received was no different between both groups. Both treatment arms improved significantly. The increase in FEV1 in the combination group was 0.61 L (0.04 L) and in the salbutamol alone group was 0.52 L (0.04 L) at 90 min. There was a trend toward greater bronchodilatation in the combination group, but this did not reach statistical significance. Fewer hospitalizations, 5.9% vs 11.2%, occurred in the combination group, but this did not reach statistical significance. In conclusion, this large multicenter study failed to show a significantly better response to a combination of salbutamol and ipratropium bromide vs salbutamol alone.</abstract><cop>Northbrook, IL</cop><pub>Elsevier Inc</pub><pmid>9041974</pmid><doi>10.1378/chest.111.2.311</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0012-3692 |
ispartof | Chest, 1997-02, Vol.111 (2), p.311-315 |
issn | 0012-3692 1931-3543 |
language | eng |
recordid | cdi_proquest_journals_200457014 |
source | Alma/SFX Local Collection |
subjects | acute asthma Biological and medical sciences bronchodilator therapy ipratropium bromide Medical sciences Pharmacology. Drug treatments Respiratory system salbutamol |
title | The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T19%3A02%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Clinical%20Efficacy%20of%20Combination%20Nebulized%20Anticholinergic%20and%20Adrenergic%20Bronchodilators%20vs%20Nebulized%20Adrenergic%20Bronchodilator%20Alone%20in%20Acute%20Asthma&rft.jtitle=Chest&rft.au=FitzGerald,%20J.%20Mark&rft.aucorp=the%20Canadian%20Combivent%20Study%20Group&rft.date=1997-02-01&rft.volume=111&rft.issue=2&rft.spage=311&rft.epage=315&rft.pages=311-315&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.111.2.311&rft_dat=%3Cproquest_cross%3E13306884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=200457014&rft_id=info:pmid/9041974&rft_els_id=S0012369215525269&rfr_iscdi=true |